Skip to content

Correlation between changes in serological indicators and in-stent restenosis after elective PCI in patients with coronary heart disease

Correlation between changes in serological indicators and in-stent restenosis after elective PCI in patients with coronary heart disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114917
Enrollment
Unknown
Registered
2025-12-18
Start date
2025-12-31
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease angina pectoris

Interventions

Non-in-stent restenosis group:None
In-stent restenosis group:None

Sponsors

Shiyan People's hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.In our hospital, patients with at least one main coronary artery confirmed by CAG to have a luminal stenosis >75% between January 2019 and December 2023 were successfully treated with elective PCI, and underwent repeat CAG at our hospital at an interval of 6 months or longer; 2. patients had complete medical records, received drug-eluting stent implantation during the initial CAG, and all included patients were administered secondary preventive medications for coronary heart disease.

Exclusion criteria

Exclusion criteria: 1. Patients undergoing PCI for the first time during hospitalisation who have previously undergone PCI; 2. Patients diagnosed with acute myocardial infarction during their first hospital admission undergoing emergency PCI; 3. Individuals with a history of allergy to contrast agents used during PCI procedures; 4. Patients with a history of haematological disorders, malignant tumours, congenital heart disease, valvular heart disease, or immune system disorders; 5. Patients not regularly taking secondary prevention medication for coronary heart disease; 6. Patients with incomplete clinical or coronary angiography data, or poor compliance.

Design outcomes

Primary

MeasureTime frame
Blood Lipid Profile;

Secondary

MeasureTime frame
Serum Albumin;Serum Albumin;Coagulation Function;Serum Total Bilirubin;Complete Blood Count;Serum Uric Acid;Renal Function;

Countries

China

Contacts

Public ContactZhangzhixin

Shiyan People's hospital

317892976@qq.com+86 719 8637035

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026